“This collaboration reinforces a shared commitment to the development of specialty enzymes. Novo Nordisk Pharmatech brings market knowledge and the required production-quality capabilities, while Novozymes brings a large enzyme library and strong R&D competencies. Together, this positions us well to create new and innovative products for this market,” said Lotte Clemmen Christensen, vice president, corporate strategy & new business development at Novozymes. 

The partners expect to bring a first product to commercialization within a few years.

Author: Elaine Burridge, Freelance Journalist